Capricor Therapeutics, Inc. (CAPR) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Capricor Therapeutics, Inc.
Address
10865 Road to the Cure
San Diego, CA 92121
United States of America (the)
Phone
310 358 3200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
231
First IPO Date
February 13, 2007
Key Executives
| Name | Title | Pay | Year Born |
| Linda Marbán | Co-Founder, President, Chief Executive Officer & Director | 580,645 | 1963 |
| Frank Isaac Litvack FACC | Executive Chairman of the Board | 120,000 | 1956 |
| Karen G. Krasney | Executive Vice President, General Counsel & Secretary | 500,718 | 1953 |
| Anthony J. Bergmann | Chief Financial Officer & Corporate Treasurer | 584,750 | 1986 |
| Kristi A. H. Elliott | Chief Operating & Science Officer | 0 | N/A |
| Michael Maurer | Chief Commercial Officer | 0 | N/A |
| Mark Awadalla | Chief Development Officer | 0 | N/A |
| Minghao Sun | Senior Vice President of Quality Control, Research & Product Development | 0 | N/A |
| Nathaniel Hogan | Director of Biostatistics of Capricor Therapeutics | 0 | N/A |
| Catherine Lee Kelleher | Consultant | 0 | N/A |
| Micheal Binks | Chief Medical Officer | 0 | N/A |
AD
Description
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
AD
